GDNF control of the glutamatergic cortico-striatal pathway requires tonic activation of adenosine A2A receptors

Journal of Neurochemistry

Volumn 108, Issue 5, 2009, Pages 1208-1219

  Gomes, Catarina A R V ^a   Simões, Patrícia F ^b   Canas, Paula M ^b   Quiroz, César ^c   Sebastião, Ana M ^a   Ferré, Sergi ^c   Cunha, Rodrigo A ^b   Ribeiro, Joaquim A ^a  

^a INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

A2A receptor; Adenosine; Cortico striatal pathway; Glial cell line derived neurotrophic factor; Glutamate; Rearranged during transfection GDNF family receptor 1

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR RECEPTOR; GLUTAMIC ACID; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR GLUTAMATE TRANSPORTER 2;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN SYNAPTOSOME; CORPUS STRIATUM; ELECTROSTIMULATION; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; RAT; SPRAGUE DAWLEY RAT; SYNAPTOSOME; WISTAR RAT;

ADENOSINE; ANIMALS; CEREBRAL CORTEX; CORPUS STRIATUM; ELECTRIC STIMULATION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR RECEPTORS; GLUTAMIC ACID; NEURAL PATHWAYS; PHENETHYLAMINES; POTASSIUM CHLORIDE; PROTO-ONCOGENE PROTEINS C-RET; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, PURINERGIC P1; SUBCELLULAR FRACTIONS; SYNAPSES; SYNAPTOPHYSIN; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; SYNAPTOSOMES;

RATTUS;

EID: 59449098460     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.05876.x     Document Type: Article

References (42)

1. Alberch J., Pérez-Navarro E. Canals J. M. (2004) Neurotrophic factors in Huntington's disease. Prog. Brain Res. 146, 195 229.
2. Barker R. A. (2006) Continuing trials of GDNF in Parkinson's disease. Lancet Neurol. 5, 285 286.
3. Calabresi P., Picconi B., Tozzi A. Di Filippo M. (2007) Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci. 30, 211 219.
4. Cepeda C., Wu N., André V. M., Cummings D. M. Levine M. S. (2007) The corticostriatal pathway in Huntington's disease. Prog. Neurobiol. 81, 253 271.
5. 2A receptor heteromers. J. Neurosci. 26, 2080 2087.
6. Coleman M. P. Perry V. H. (2002) Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 25, 532 537.
7. D'Alcantara P., Ledent C., Swillens S. Schiffmann S. N. (2001) Inactivation of adenosine A2A receptors impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 107, 455 464.
8. Dauer W. Przedborski S. (2003) Parkinson's disease: mechanisms and models. Neuron 39, 889 909.
9. Day M., Wang Z., Ding J. et al. (2006) Selective elimination of glutamatergic synapses on striatopallidal neurons in Parkinson disease models. Nat. Neurosci. 9, 251 259.
10. 2A receptor facilitates brain-derived neurotrophic factor modulation of synaptic transmission in hippocampal slices. J. Neurosci. 24, 2905 2913.
11. 2A receptors. Hippocampus 17, 577 585.
12. Fernandes C. C., Pinto-Duarte A., Sebastião A. M. Ribeiro J. A. (2008) Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons. J. Neurosci. 28, 5611 5618.
13. Ferré S., Borycz J., Goldberg S. R., Hope B. T., Morales M., Lluis C., Franco R., Ciruela F. Cunha R. A. (2005) Role of adenosine in the control of homosynaptic plasticity in striatal excitatory synapses. J. Integr. Neurosci. 4, 445 464.
14. Ferré S., Ciruela F., Woods A. S., Lluis C. Franco R. (2007) Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci. 30, 440 446.
15. 2A receptor activation by endogenous adenosine. Neuropharmacology 54, 924 933.
16. Gash D. M., Zhang Z., Ovadia A., Cass W. A., Yi A., Simmerman L., Russell D. Martin D. (1996) Functional recovery in Parkinsonian monkeys treated with GDNF. Nature 380, 252 255.
17. Gerfen G. R. (2004) Basal ganglia, in The Rat Nervous System (Paxinos G., ed). Elsevier Academic Press, Amsterdam.
18. 2A receptor-dependent manner. Brain Res. 1113, 129 136.
19. Hurelbrink C. B. Barker R. A. (2004) The potential of GDNF as a treatment for Parkinson's disease. Exp. Neurol. 185, 1 6.
20. 2 receptor in rat brain. J. Pharmacol. Exp. Ther. 251, 888 893.
21. 2A receptor-mediated expression of c-fos. Eur. J. Neurosci. 18, 296 302.
22. Kramer E. R., Aron L., Ramakers G. M., Seitz S., Zhuang X., Beyer K., Smidt M. P. Klein R. (2007) Absence of Ret signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol. 5, e39.
23. 2A receptor antagonist istradefylline (KW-6002) reduces 'off' time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 63, 295 302.
24. Li H., Li S. H., Yu Z. X., Shelbourne P. Li X. J. (2001) Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 21, 8473 8481.
25. Li J. Y., Plomann M. Brundin P. (2003) Huntington's disease: a synaptopathy? Trends Mol. Med. 9, 414 420.
26. Lipton S. A. Rosenberg P. A. (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N. Engl. J. Med. 330, 613 622.
27. Lopes L. V., Cunha R. A., Kull B., Fredholm B. B. Ribeiro J. A. (2002) Adenosine A(2A) receptor facilitation of hippocampal synaptic transmission is dependent on tonic A(1) receptor inhibition. Neuroscience 112, 319 329.
28. Mojsilovic-Petrovic J., Jeong G. B., Crocker A., Arneja A., David S., Russell D. S. Kalb R. G. (2006) Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J. Neurosci. 26, 9250 9263.
29. Patel N. K., Bunnage M., Plaha P., Svendsen C. N., Heywood P. Gill S. S. (2005) Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann. Neurol. 57, 298 302.
30. 2A receptors in Huntington's disease. Prog. Neurobiol. 81, 331 348.
31. 2A receptors. Neurosci. Lett. 404, 143 147.
32. 2A receptors prevents protein phosphorylation in the striatum induced by cortical stimulation. J. Neurosci. 26, 10808 10812.
33. 2A receptors in the hippocampus and striatum of rat. Neuroscience 132, 893 903.
34. 2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 92, 433 441.
35. Sariola H. Saarma M. (2003) Novel functions and signalling pathways for GDNF. J. Cell Sci. 116, 3855 3862.
36. Schatz D. S., Kaufmann W. A., Saria A. Humpel C. (1999) Dopamine neurons in a simple GDNF-treated meso-striatal organotypic co-culture model. Exp. Brain Res. 127, 270 278.
37. 2A receptors and basal ganglia physiology. Prog. Neurobiol. 83, 277 292.
38. 2A receptors. Prog. Neurobiol. 59, 355 396.
39. Tomac A., Lindqvist E., Lin L. F., Ogren S. O., Young D., Hoffer B. J. Olson L. (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373, 335 339.
40. 2A-R contributes to motoneuron survival by transactivating the tyrosine kinase receptor TrkB. Proc. Natl Acad. Sci. USA 104, 17210 17215.
41. Wishart T. M., Parson S. H. Gillingwater T. H. (2006) Synaptic vulnerability in neurodegenerative disease. J. Neuropathol. Exp. Neurol. 65, 733 739.
42. Zocchi C., Ongini E., Conti A., Monopoli A., Negretti A., Baraldi P. G. Dionisotti S. (1996) The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2A adenosine receptor antagonist. J. Pharmacol. Exp. Ther. 276, 398 404.